-
1
-
-
84879684477
-
Enzyme replacement therapy for mucopolysaccharidosis VI: Long-term cardiac effects of galsulfase (Naglazyme(R)) therapy
-
3590402 22669363 10.1007/s10545-012-9481-2
-
Braunlin E, Rosenfeld H, Kampmann C et al (2013) Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(R)) therapy. J Inherit Metab Dis 36:385-394
-
(2013)
J Inherit Metab Dis
, vol.36
, pp. 385-394
-
-
Braunlin, E.1
Rosenfeld, H.2
Kampmann, C.3
-
2
-
-
0030658865
-
Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI
-
9356736 10.1016/S8756-3282(97)00175-0
-
Byers S, Nuttall JD, Crawley AC, Hopwood JJ, Smith K, Fazzalari NL (1997) Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Bone 21:425-431
-
(1997)
Bone
, vol.21
, pp. 425-431
-
-
Byers, S.1
Nuttall, J.D.2
Crawley, A.C.3
Hopwood, J.J.4
Smith, K.5
Fazzalari, N.L.6
-
3
-
-
0031029536
-
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI
-
507847 9045867 10.1172/JCI119208
-
Crawley AC, Niedzielski KH, Isaac EL, Davey RC, Byers S, Hopwood JJ (1997) Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest 99:651-662
-
(1997)
J Clin Invest
, vol.99
, pp. 651-662
-
-
Crawley, A.C.1
Niedzielski, K.H.2
Isaac, E.L.3
Davey, R.C.4
Byers, S.5
Hopwood, J.J.6
-
4
-
-
77954629021
-
Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase
-
2904323 20634905
-
Decker C, Yu ZF, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 3:89-100
-
(2010)
J Pediatr Rehabil Med
, vol.3
, pp. 89-100
-
-
Decker, C.1
Yu, Z.F.2
Giugliani, R.3
-
5
-
-
0026580312
-
The Denver II: A major revision and restandardization of the Denver Developmental Screening Test
-
1370185
-
Frankenburg WK, Dodds J, Archer P, Shapiro H, Bresnick B (1992) The Denver II: a major revision and restandardization of the Denver Developmental Screening Test. Pediatrics 89:91-97
-
(1992)
Pediatrics
, vol.89
, pp. 91-97
-
-
Frankenburg, W.K.1
Dodds, J.2
Archer, P.3
Shapiro, H.4
Bresnick, B.5
-
6
-
-
82255179466
-
Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI
-
21930407 10.1016/j.ymgme.2011.08.029
-
Furujo M, Kubo T, Kosuga M, Okuyama T (2011) Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol Genet Metab 104:597-602
-
(2011)
Mol Genet Metab
, vol.104
, pp. 597-602
-
-
Furujo, M.1
Kubo, T.2
Kosuga, M.3
Okuyama, T.4
-
7
-
-
0034633090
-
Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses
-
11179586 10.1016/S0188-4409(00)00104-1
-
Gallegos-Arreola MP, Machorro-Lazo MV, Flores-Martinez SE et al (2000) Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses. Arch Med Res 31:505-510
-
(2000)
Arch Med Res
, vol.31
, pp. 505-510
-
-
Gallegos-Arreola, M.P.1
Machorro-Lazo, M.V.2
Flores-Martinez, S.E.3
-
8
-
-
34547682071
-
Management guidelines for mucopolysaccharidosis VI
-
17671068 10.1542/peds.2006-2184
-
Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120:405-418
-
(2007)
Pediatrics
, vol.120
, pp. 405-418
-
-
Giugliani, R.1
Harmatz, P.2
Wraith, J.E.3
-
9
-
-
27744493202
-
Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase
-
15930196 10.1542/peds.2004-1023
-
Harmatz P, Ketteridge D, Giugliani R et al (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115:e681-e689
-
(2005)
Pediatrics
, vol.115
-
-
Harmatz, P.1
Ketteridge, D.2
Giugliani, R.3
-
10
-
-
33744978567
-
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
-
16647419 10.1016/j.jpeds.2005.12.014
-
Harmatz P, Giugliani R, Schwartz I et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148:533-539
-
(2006)
J Pediatr
, vol.148
, pp. 533-539
-
-
Harmatz, P.1
Giugliani, R.2
Schwartz, I.3
-
11
-
-
46949093352
-
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
-
18502162 10.1016/j.ymgme.2008.04.001
-
Harmatz P, Giugliani R, Schwartz IV et al (2008) Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94:469-475
-
(2008)
Mol Genet Metab
, vol.94
, pp. 469-475
-
-
Harmatz, P.1
Giugliani, R.2
Schwartz, I.V.3
-
12
-
-
84879688261
-
Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)
-
22127392 10.1007/s10545-011-9410-9
-
Hendriksz CJ, Giugliani R, Harmatz P et al (2013) Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis 36:373-384
-
(2013)
J Inherit Metab Dis
, vol.36
, pp. 373-384
-
-
Hendriksz, C.J.1
Giugliani, R.2
Harmatz, P.3
-
13
-
-
2642573491
-
Early diagnosis of Maroteaux-Lamy syndrome in two patients with accelerated growth and advanced bone maturation
-
15346915 10.1007/s00431-004-1428-7
-
Heron D, Baumann C, Benichou JJ, Harpey JP, Le Merrer M (2004) Early diagnosis of Maroteaux-Lamy syndrome in two patients with accelerated growth and advanced bone maturation. Eur J Pediatr 163:323-326
-
(2004)
Eur J Pediatr
, vol.163
, pp. 323-326
-
-
Heron, D.1
Baumann, C.2
Benichou, J.J.3
Harpey, J.P.4
Le Merrer, M.5
-
14
-
-
84876092083
-
Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI
-
23535281 10.1016/j.ymgme.2013.02.014
-
Horovitz DD, Magalhaes TS, Acosta A et al (2013) Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab 109:62-69
-
(2013)
Mol Genet Metab
, vol.109
, pp. 62-69
-
-
Horovitz, D.D.1
Magalhaes, T.S.2
Acosta, A.3
-
15
-
-
0036311539
-
A common metric for the Griffiths Scales
-
1719193 12138056 10.1136/adc.87.2.109
-
Ivens J, Martin N (2002) A common metric for the Griffiths Scales. Arch Dis Child 87:109-110
-
(2002)
Arch Dis Child
, vol.87
, pp. 109-110
-
-
Ivens, J.1
Martin, N.2
-
17
-
-
70349555987
-
2000 CDC Growth Charts for the United States: Methods and development
-
Kuczmarski RJ, Ogden CL, Guo SS et al (2002) 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11:1-190
-
(2002)
Vital Health Stat
, vol.11
, pp. 1-190
-
-
Kuczmarski, R.J.1
Ogden, C.L.2
Guo, S.S.3
-
18
-
-
77954633206
-
Radiologic and neuroradiologic findings in the mucopolysaccharidoses
-
21791838
-
Lachman R, Martin KW, Castro S, Basto MA, Adams A, Teles EL (2010) Radiologic and neuroradiologic findings in the mucopolysaccharidoses. J Pediatr Rehabil Med 3:109-118
-
(2010)
J Pediatr Rehabil Med
, vol.3
, pp. 109-118
-
-
Lachman, R.1
Martin, K.W.2
Castro, S.3
Basto, M.A.4
Adams, A.5
Teles, E.L.6
-
19
-
-
77953049350
-
Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study
-
19968667 10.1111/j.1399-0004.2009.01324.x
-
McGill JJ, Inwood AC, Coman DJ et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study. Clin Genet 77:492-498
-
(2010)
Clin Genet
, vol.77
, pp. 492-498
-
-
McGill, J.J.1
Inwood, A.C.2
Coman, D.J.3
-
20
-
-
43049096056
-
Growth charts for patients affected with Morquio A disease
-
18412124 10.1002/ajmg.a.32281
-
Montano AM, Tomatsu S, Brusius A, Smith M, Orii T (2008) Growth charts for patients affected with Morquio A disease. Am J Med Genet A 146A:1286-1295
-
(2008)
Am J Med Genet A
, vol.146
, pp. 1286-1295
-
-
Montano, A.M.1
Tomatsu, S.2
Brusius, A.3
Smith, M.4
Orii, T.5
-
21
-
-
20144386995
-
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
-
15690405 10.1002/ajmg.a.30579
-
Swiedler SJ, Beck M, Bajbouj M et al (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A 134A:144-150
-
(2005)
Am J Med Genet A
, vol.134
, pp. 144-150
-
-
Swiedler, S.J.1
Beck, M.2
Bajbouj, M.3
-
22
-
-
84867884581
-
Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: A case series
-
22441840 10.1007/s10545-012-9474-1
-
Thumler A, Miebach E, Lampe C et al (2012) Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series. J Inherit Metab Dis 35:1071-1079
-
(2012)
J Inherit Metab Dis
, vol.35
, pp. 1071-1079
-
-
Thumler, A.1
Miebach, E.2
Lampe, C.3
-
24
-
-
0024520993
-
Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion
-
2493341
-
Whitley CB, Ridnour MD, Draper KA, Dutton CM, Neglia JP (1989) Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 35:374-379
-
(1989)
Clin Chem
, vol.35
, pp. 374-379
-
-
Whitley, C.B.1
Ridnour, M.D.2
Draper, K.A.3
Dutton, C.M.4
Neglia, J.P.5
-
25
-
-
84860194402
-
Expert recommendations for the laboratory diagnosis of MPS VI
-
22405600 10.1016/j.ymgme.2012.02.005
-
Wood T, Bodamer OA, Burin MG et al (2012) Expert recommendations for the laboratory diagnosis of MPS VI. Mol Genet Metab 106:73-82
-
(2012)
Mol Genet Metab
, vol.106
, pp. 73-82
-
-
Wood, T.1
Bodamer, O.A.2
Burin, M.G.3
|